Lupin
LUPIN · Pharma > Pharmaceuticals & Drugs · Chairman: Manju D Gupta · MD: Nilesh Gupta · Listing date: Sept. 11, 2001 · Employees: 18573 · Mumbai · http://www.lupin.com

Stock Price vs Company Growth
1d
0.5%
1w
1.1%
1m
10.4%
3m
28.9%
6m
44.8%
1y
144.5%
5y
16.3%
10y
5.8%
all
17.0%

Use @ for users, # for companies and : for emojis
 
 
 
 
Last Traded Price

₹ 1,605 0.5%
1,200
1,701
Company Overview

Sales
19,480 Cr
Growth: 14.8%
Profit after Tax
1,791 Cr
Growth: 34.5%
Large Cap
73,117 Cr
P/E: 40.9x
Industry P/E: 34.3x
Fundamentals

Sales (Cr) ₹ 19,480
Growth 14.8%
EBITDA 17.3%
P/S 3.8x
Dividend 0.6%
P/E 40.9x
Book Value ₹ 308
PEG Ratio 2.8x
ROE 13.6%
P/B 5.2x
Shareholding Pattern

Institutions
Life Insurance Corporation Of India
6.99 %
Hdfc Trustee Company Limited-Hdfc Flexi Cap Fund
4.28 %
Government Pension Fund Global
1.21 %
Franklin India Focused Equity Fund
1.13 %
Icici Prudential Life Insurance Company Limited
1.13 %
Promoters
Lupin Investments Pvt Ltd
45.3 %
Manju D Gupta
0.85 %
Nilesh D Gupta
0.2 %
Anuja Gupta
0.16 %
Desh Bandhu Gupta Huf
0.14 %
Others
Rakesh Jhunjhunwala
1.6 %
Nps Trust - A/C Lic Pension Fund Sch-State Govt
1.48 %
Iepf
0.15 %
Increase    Decrease    No change
Company Profile Detailed

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India.Products and services offered by the companyGlobal FormulationsActive Pharmaceuticals Ingredients (API)BiotechSpecialty BusinessOver The Counter (OTC)Global Manufacturing & Supply ChainAwards2007: Cardinal Health Conferred Two Awards - The ‘Trade Representative Of The Year’ And The ‘Quality Supplier Award’ To Lupin Pharmaceuticals Inc.
Investors (229)
Followers (55)